Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Accenture
Healthtrust
Moodys
Dow
Johnson and Johnson
McKesson
Queensland Health
Chinese Patent Office
Baxter

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,224,905

« Back to Dashboard

Which drugs does patent 6,224,905 protect, and when does it expire?

Patent 6,224,905 protects RISPERDAL and is included in one NDA.

Protection for RISPERDAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in twenty-seven countries.
Summary for Patent: 6,224,905
Title: Biconvex rapidly disintegrating dosage forms
Abstract:A method for preparing solid rapidly disintegrating dosage forms shaped as biconvex tablets having symmetrical top and bottom surfaces and dosage forms obtainable thereby.
Inventor(s): Lawrence; Janice (Gregory, MI), Posage; Gary (Rochester Hills, MI)
Assignee: Janssen Pharmaceutica N.V. (BE)
Application Number:09/194,808
Patent Claim Types:
see list of patent claims
Dosage form; Process; Composition; Formulation;

Drugs Protected by US Patent 6,224,905

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-001 Apr 2, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-002 Apr 2, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-003 Apr 2, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-004 Dec 23, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms RISPERDAL risperidone TABLET, ORALLY DISINTEGRATING;ORAL 021444-005 Dec 23, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,224,905

PCT Information
PCT FiledJune 10, 1997PCT Application Number:PCT/EP97/03065
PCT Publication Date:December 24, 1997PCT Publication Number: WO97/48383

International Patents Family Members for US Patent 6,224,905

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 213154 ➤ Subscribe
Australia 3175797 ➤ Subscribe
Australia 713062 ➤ Subscribe
Brazil 9709829 ➤ Subscribe
Canada 2257303 ➤ Subscribe
China 1191824 ➤ Subscribe
China 1222075 ➤ Subscribe
Cyprus 2288 ➤ Subscribe
Czech Republic 297261 ➤ Subscribe
Czech Republic 9804124 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
Cipla
Fish and Richardson
Express Scripts
Julphar
Moodys
McKesson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot